查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600758

月经治疗药物市场：按类型、治疗方法、分销管道和最终用户分类 - 全球预测 2025-2030

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Medication, Surgery, Therapeutics), Distribution Channel, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年月经痛治疗市场价值为71.6亿美元，预计到2024年将达到78亿美元，复合年增长率为8.98%，到2030年将达到130.9亿美元。

月经药物市场包括一系列旨在缓解月经痛的药物、设备和替代疗法，经痛困扰着世界上很大一部分女性人口。月经的高盛行率及其对生活品质、生产力和心理健康的影响推动了对这些治疗的需求。应用范围从非类固醇消炎剂(NSAID) 等非处方止痛药到荷尔蒙疗法以及经皮神经电刺激 (TENS) 和针灸等新型干预措施。主要最终用户包括医院、诊所和寻求家庭救济的个人消费者。推动市场成长的是意识的提高、获得医疗保健的机会的改善以及实现个人化医疗的生物技术的进步。人们对非侵入性替代医学日益增长的兴趣正在进一步扩大治疗范围。然而，传统治疗方法的副作用、欠发达地区缺乏认识以及监管障碍等挑战构成了主要障碍。市场参与企业必须克服这些限制，同时透过对侵入性较小、更有效的解决方案进行创新研究来解决未满足的需求，例如神经刺激和穿戴式科技的突破性应用。支持妇女健康的政府政策和增加研发投资带来了庞大的商机。抓住这些机会的建议包括加强教育、关注服务不足的市场以及促进与医疗保健提供者的合作以提高产品的采用率和信任度。此外，强调透过自然疗法和生物技术开发无副作用的治疗方法也可能吸引消费者的兴趣。对市场特征的考虑表明，竞争格局正在随着科学的进步而演变，消费者的偏好正在转向整体健康方法，并且人们越来越重视结合药品和技术进步的综合解决方案。创新成熟的关键领域包括数位健康与即时监测的集成，以及探索符合最少干预和负担能力偏好的替代疼痛管理技术。

主要市场统计
基准年[2023] 71.6亿美元
预测年份 [2024] 78亿美元
预测年份 [2030] 130.9亿美元
复合年增长率（%） 8.98%

市场动态：快速发展的月经药物市场的关键市场洞察

供需的动态交互作用正在改变月经药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 月经的盛行率以及有效治疗方案的需求
    • 提高对妇女生殖健康的认识以及政府扩大妇女医疗保健的努力
  • 市场限制因素
    • 月经药物及器材产品召回相关问题
  • 市场机会
    • 月经治疗进展及新药出现
    • 穿戴式科技的采用和数位健康的普及
  • 市场挑战
    • 月经管理的社会障碍与污名化

波特五力：驾驭月经药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对月经治疗药物市场的影响

外部宏观环境因素对月经治疗药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解月经治疗药物市场的竞争状况

对月经治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 经痛药市场厂商定位月经绩效评估

FPNV定位矩阵是评估月经治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 月经的盛行率以及有效治疗方法的必要性
      • 人们对妇女生殖健康的认识不断提高，政府努力扩大妇女的医疗保健
    • 抑制因素
      • 月经药品及医疗设备产品召回相关问题
    • 机会
      • 月经治疗的进展和新药的出现
      • 穿戴式科技的引入和数位健康的传播
    • 任务
      • 关于月经治疗的社会障碍与耻辱
  • 市场区隔分析
    • 类型：原发性经痛很常见，需要广泛的止痛治疗。
    • 治疗：以子宫切除治疗，永久缓解月经
    • 分销管道：由于药品和止痛贴片的便利性、保密性和有竞争力的价格，线上药局越来越受到青睐。
    • 最终使用者：由于月经药物易于取得且具有成本效益，因此越来越多地在家庭护理领域被采用。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章月经治疗药物市场：依类型

  • 原发性经痛
  • 次发性月经

第七章依治疗方式分類的月经治疗药物市场

  • 药物治疗
    • 复方口服避孕药
    • COX-2抑制剂
    • 非类固醇消炎剂
    • 非处方药
    • 经皮三硝酸甘油酯
  • 外科手术
    • 子宫切除术
    • 子宫内避孕器
    • 腹腔镜荐骨神经切除术
    • levonorgestrel子宫内避孕系统 (LN-IUS)
    • 骶前切除术
  • 治疗药物
    • 替代疗法
    • 心理治疗

第八章月经治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章月经治疗药物市场：依最终使用者分类

  • 居家护理
  • 医院
  • 专科诊所

第十章 北美和南美月经治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区月经治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的月经药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Mithra 申请在日本核准用于治疗月经
    • Chime Biologics与Hope Medicine签署生产协议，加速推出首个针对子宫内膜异位症和雄性秃的抗体医药品HMI-115
    • Mithra 从富士製药接受250 万欧元用于日本月经治疗
    • 住友製药和辉瑞公司在加拿大获得加拿大卫生署核准MYFEMBREE
    • Gedeon Richter 和住友製药获得 CHMP 对子宫内膜异位症治疗 RYEQO 的正面意见
    • 蒙特娄的新技术可以帮助缓解经期疼痛
    • Chugai Pharmaceutical 和 Bioformis 建立新的合作关係，专注于资料驱动的虚拟护理，治疗与子宫内膜异位症相关的疼痛
    • Dare Bioscience开始治疗原发性经痛的一期试验
    • 健康科技Start-UpsOvira 正在帮助女性解决无需药物即可缓解疼痛的重要问题。
    • 凭藉新的美丽灵感设计和扩展的健康产品组合，Cora 重新构想了经期护理，让每个人都感觉更好。

公司名单

  • Abbott Laboratories
  • AA Pharma Inc.
  • Cora Life by LYV Life, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Alfa Pharma GmbH
  • ASKA Pharmaceutical Co., Ltd.
  • Bayer AG
  • Lupin Pharmaceuticals, Inc.
  • Myoovi
  • Viatris Inc.
  • Myovant Sciences by Sumitovant Biopharma, Inc.
  • Sanofi SA
  • Cumberland Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Comforte Cream by PMS4PMS, LLC
  • Micro Labs Limited
  • LGM Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Gedeon Richter Plc.
  • Alvogen, Inc.
  • Endo Pharmaceuticals Inc.
  • Perrigo Company PLC
  • Teva Pharmaceutical Industries Ltd.
  • Ovira
  • Ferring BV
  • F. Hoffmann-La Roche AG
  • Rael, Inc.
  • Novartis AG
  • Haleon PLC
  • Johnson & Johnson Services, Inc.
  • Hikma Pharmaceuticals PLC
  • Livia by iPulse Medical Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-742BD517DA92

The Dysmenorrhea Treatment Market was valued at USD 7.16 billion in 2023, expected to reach USD 7.80 billion in 2024, and is projected to grow at a CAGR of 8.98%, to USD 13.09 billion by 2030.

The dysmenorrhea treatment market encompasses a range of pharmaceuticals, devices, and alternative therapies aimed at alleviating menstrual pain, which afflicts a substantial segment of the global female population. The necessity for these treatments is driven by the high prevalence of dysmenorrhea and its impact on quality of life, productivity, and mental health. Applications range from over-the-counter pain relievers, such as NSAIDs, to hormonal therapies and novel interventions like transcutaneous electrical nerve stimulation (TENS) and acupuncture. Key end-users include hospitals, clinics, and individual consumers seeking at-home relief options. Market growth is propelled by increasing awareness, improved healthcare access, and advances in biotechnology enabling personalized medicine. A growing interest in non-invasive and alternative medicine further expands the treatment scope. Nevertheless, challenges such as side effects of conventional therapies, lack of awareness in underdeveloped regions, and regulatory hurdles pose significant barriers. Market participants must navigate these limitations while addressing the unmet needs through innovative research into less invasive and more effective solutions, like breakthrough applications in neurostimulation and wearable technology. Governmental policies supporting women's health and rising investment in R&D present robust opportunities. Recommendations for capturing these opportunities include ramping up education efforts, focusing on under-served markets, and fostering collaborations with healthcare providers to expand product reach and endorse trust. Emphasizing the development of side-effect-free treatments through natural or biotechnological means could also capture consumer interest. Insights into the nature of the market reveal a competitive landscape that is evolving with scientific progress, consumer preferences shifting towards holistic health approaches, and a growing emphasis on integrated solutions combining medicinal and technological advancements. Key areas ripe for innovation include digital health integration with real-time monitoring and the exploration of alternative pain management techniques that align with preferences for minimal intervention and enhanced affordability.

KEY MARKET STATISTICS
Base Year [2023] USD 7.16 billion
Estimated Year [2024] USD 7.80 billion
Forecast Year [2030] USD 13.09 billion
CAGR (%) 8.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dysmenorrhea Treatment Market

The Dysmenorrhea Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of dysmenorrhea and the need for effective treatment options
    • Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
  • Market Restraints
    • Issues associated with product recalls for dysmenorrhea drugs and devices
  • Market Opportunities
    • Advancements in therapy for dysmenorrhea and the emergence of novel drugs
    • Adoption of wearable technology and the proliferation of digital health
  • Market Challenges
    • Societal barriers and stigmatization regarding dysmenorrhea management

Porter's Five Forces: A Strategic Tool for Navigating the Dysmenorrhea Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dysmenorrhea Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dysmenorrhea Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dysmenorrhea Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dysmenorrhea Treatment Market

A detailed market share analysis in the Dysmenorrhea Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dysmenorrhea Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dysmenorrhea Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Dysmenorrhea Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AA Pharma Inc., Cora Life by LYV Life, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited., Merck & Co., Inc., AbbVie Inc., Alfa Pharma GmbH, ASKA Pharmaceutical Co., Ltd., Bayer AG, Lupin Pharmaceuticals, Inc., Myoovi, Viatris Inc., Myovant Sciences by Sumitovant Biopharma, Inc., Sanofi S.A., Cumberland Pharmaceuticals Inc., GlaxoSmithKline PLC, Comforte Cream by PMS4PMS, LLC, Micro Labs Limited, LGM Pharma, Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Alvogen, Inc., Endo Pharmaceuticals Inc., Perrigo Company PLC, Teva Pharmaceutical Industries Ltd., Ovira, Ferring B.V., F. Hoffmann-La Roche AG, Rael, Inc., Novartis AG, Haleon PLC, Johnson & Johnson Services, Inc., Hikma Pharmaceuticals PLC, Livia by iPulse Medical Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Dysmenorrhea Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Primary Dysmenorrhea and Secondary Dysmenorrhea.
  • Based on Treatment, market is studied across Medication, Surgery, and Therapeutics. The Medication is further studied across Combined Oral Contraceptive Pills, Cox-2 Inhibitors, Non-Steroidal Anti-Inflammatory Drugs, Over-The-Counter Medications, and Transdermal Glyceryl Trinitrate. The Surgery is further studied across Hysterectomy, Intrauterine Device, Laparoscopic Uterosacral Nerve Ablation, Levonorgestrel Intrauterine System (LN-IUS), and Presacral Neurectomy. The Therapeutics is further studied across Alternative Therapies and Psychological Therapies.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of dysmenorrhea and the need for effective treatment options
      • 5.1.1.2. Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls for dysmenorrhea drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapy for dysmenorrhea and the emergence of novel drugs
      • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
    • 5.1.4. Challenges
      • 5.1.4.1. Societal barriers and stigmatization regarding dysmenorrhea management
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management
    • 5.2.2. Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea
    • 5.2.3. Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches
    • 5.2.4. End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dysmenorrhea Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Primary Dysmenorrhea
  • 6.3. Secondary Dysmenorrhea

7. Dysmenorrhea Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
    • 7.2.1. Combined Oral Contraceptive Pills
    • 7.2.2. Cox-2 Inhibitors
    • 7.2.3. Non-Steroidal Anti-Inflammatory Drugs
    • 7.2.4. Over-The-Counter Medications
    • 7.2.5. Transdermal Glyceryl Trinitrate
  • 7.3. Surgery
    • 7.3.1. Hysterectomy
    • 7.3.2. Intrauterine Device
    • 7.3.3. Laparoscopic Uterosacral Nerve Ablation
    • 7.3.4. Levonorgestrel Intrauterine System (LN-IUS)
    • 7.3.5. Presacral Neurectomy
  • 7.4. Therapeutics
    • 7.4.1. Alternative Therapies
    • 7.4.2. Psychological Therapies

8. Dysmenorrhea Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Dysmenorrhea Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Dysmenorrhea Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dysmenorrhea Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dysmenorrhea Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea
    • 13.3.2. Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
    • 13.3.3. Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan
    • 13.3.4. Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
    • 13.3.5. Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO for Treatment of Endometriosis
    • 13.3.6. How New Tech from Montreal Could Help the Fight Against Period Cramps
    • 13.3.7. Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
    • 13.3.8. Dare Bioscience Begins Phase I Trial of Primary Dysmenorrhea Therapy
    • 13.3.9. Healthtech Startup Ovira is Helping Women Tackle a Key Problem - Drug-Free Period Pain Relief
    • 13.3.10. Cora Reimagines Period Care with a New Beauty-Inspired Look and Expanded Wellness Portfolio to Make Comfort Accessible for Everyone

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AA Pharma Inc.
  • 3. Cora Life by LYV Life, Inc.
  • 4. Pfizer Inc.
  • 5. Takeda Pharmaceutical Company Limited.
  • 6. Merck & Co., Inc.
  • 7. AbbVie Inc.
  • 8. Alfa Pharma GmbH
  • 9. ASKA Pharmaceutical Co., Ltd.
  • 10. Bayer AG
  • 11. Lupin Pharmaceuticals, Inc.
  • 12. Myoovi
  • 13. Viatris Inc.
  • 14. Myovant Sciences by Sumitovant Biopharma, Inc.
  • 15. Sanofi S.A.
  • 16. Cumberland Pharmaceuticals Inc.
  • 17. GlaxoSmithKline PLC
  • 18. Comforte Cream by PMS4PMS, LLC
  • 19. Micro Labs Limited
  • 20. LGM Pharma
  • 21. Dr. Reddy's Laboratories Ltd.
  • 22. Gedeon Richter Plc.
  • 23. Alvogen, Inc.
  • 24. Endo Pharmaceuticals Inc.
  • 25. Perrigo Company PLC
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Ovira
  • 28. Ferring B.V.
  • 29. F. Hoffmann-La Roche AG
  • 30. Rael, Inc.
  • 31. Novartis AG
  • 32. Haleon PLC
  • 33. Johnson & Johnson Services, Inc.
  • 34. Hikma Pharmaceuticals PLC
  • 35. Livia by iPulse Medical Ltd.
  • 36. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. DYSMENORRHEA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DYSMENORRHEA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DYSMENORRHEA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TRANSDERMAL GLYCERYL TRINITRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPIC UTEROSACRAL NERVE ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LEVONORGESTREL INTRAUTERINE SYSTEM (LN-IUS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESACRAL NEURECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PSYCHOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 328. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023